Nurix Therapeutics, Inc. (NRIX) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Nurix Therapeutics’s revenue went from $31M in fiscal 2019 to $84M in fiscal 2025, growth of about 18.0% a year.
Net income in fiscal 2025 was -$264M, a net margin of -314.9%; the best year in this period was 2019 with -$22M.
Over the twelve months to August 31, 2026, revenue was $702M and net income $295M.
Free cash flow was -$263M in fiscal 2025 and positive in 0 of the 7 years shown.
The diluted share count rose 2532% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $702M | $84M | $55M | $77M | $39M | $30M | $18M | $31M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $290M | -$286M | -$213M | -$155M | -$184M | -$118M | -$65M | -$22M |
| Net income | $295M | -$264M | -$194M | -$144M | -$180M | -$117M | -$43M | -$22M |
| EPS (diluted) | $2.43 | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 | $-6.59 |
| R&D | $334M | $317M | $222M | $189M | $184M | $116M | $66M | $45M |
| Revenue growth | — | +53.9% | −29.1% | +99.3% | +29.8% | +67.0% | −42.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $379M | -$249M | -$173M | -$81M | -$160M | -$84M | -$80000 | $601000 |
| Capital spending | -$10M | -$14M | -$9M | -$8M | -$12M | -$6M | -$5M | -$2M |
| Free cash flow | $370M | -$263M | -$182M | -$90M | -$172M | -$90M | -$5M | -$1M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $41M | $38M | $34M | $34M | $28M | $16M | $4M | $510000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $247M | $110M | $55M | $309M | $296M | $281M | $38M |
| Debt | — | $56M | $28M | $31M | $12M | $13M | $0 | $0 |
| Equity | — | $539M | $527M | $200M | $304M | $342M | $290M | -$58M |
| Total assets | — | $688M | $669M | $356M | $417M | $477M | $396M | $44M |
| Shares (diluted) | 116M | 87M | 67M | 54M | 49M | 43M | 16M | 3M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 41.3% | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% |
| Net margin | 42.0% | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% |
| FCF margin | 52.7% | -313.7% | -333.4% | -116.6% | -445.4% | -302.6% | -26.0% | -3.4% |
| ROIC | — | -38.0% | -30.3% | -67.1% | -58.2% | -26.2% | -15.2% | — |
| ROE | — | -49.1% | -36.7% | -71.8% | -59.4% | -34.2% | -14.9% | 37.6% |
Frequently asked questions
What is Nurix Therapeutics’s annual revenue?
$84M in fiscal 2025 and $702M over the twelve months to August 31, 2026.
How much profit does Nurix Therapeutics make?
Net income was -$264M in fiscal 2025 (net margin -314.9%).
Is Nurix Therapeutics’s revenue growing?
Yes: revenue rose 54.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.